Tag:
Arena Pharmaceuticals
Latest Headlines
Latest Headlines
DEA finally acts on Belviq, clearing Arena for diet drug's launch
The DEA has made its decision on Belviq, the weight-loss drug that's been sitting on Arena's launching pad since its FDA approval last June. Belviq is now officially a Schedule IV controlled substance, and Arena can fire up its engines for a launch next month.
Arena pulls app for weight-loss drug Belviq in EU
Arena Pharmaceuticals has decided to take its drug application and go home. The drugmaker Friday said it was giving up for now on breaking through the European wall of resistance to its weight-loss drug Belviq. The company, which got FDA approval last year, yanked its application with little explanation.
UPDATED: Arena shares sink after biotech withdraws marketing app for obesity drug in Europe
Arena Pharmaceuticals pulled the plug on its application for approval of the obesity drug Belviq with European regulators, another blow to the commercial and regulatory effort behind the treatment. The San Diego-based biotech revealed the decision to withdraw the app in its first-quarter financial report late Thursday afternoon.
Will Vivus, Arena go on a DTC binge for their obesity meds?
Just in time for New Year's resolutions, The Financial Times rounds up the latest on a new generation of obesity drugs.
Study: Eisai seizure drug delivers up to 5% weight loss
Could Eisai have an obesity drug just waiting to step onstage? The Japanese drugmaker's epilepsy treatment Zonegran helped patients lose weight--at least as much weight as patients in Arena Pharmaceuticals' ($ARNA) trial of its recently approved Belviq.
More payers than expected cover Vivus' Qsymia
Good news for Vivus: Many payers don't mind footing the bill for its weight-loss drug Qsymia. During the product's first week on the market, insurers agreed to pay for about one-third of prescriptions. That could help the drug gain traction before its rival, Arena Pharmaceuticals' Belviq, clears the Drug Enforcement Administration.
After FDA blessings for diet drugs, spotlight shines on biotechs' pioneering obesity meds
The trend could create a wealth of opportunities for the developers because of the blockbuster market for weight drugs, one that Big Pharma is unlikely to neglect despite past failures with anti-obesity meds.
Analysts eye generic threat as Vivus rolls out Qsymia
Vivus has won an early weight-loss race in the marketplace. The company launched its Qsymia treatment, beating competitor Arena Pharmaceuticals' Belviq by several months. But will it come out on top in the most important one--the contest for prescriptions and sales?
Analysts eye generic threat as Vivus rolls out Qsymia
Vivus ($VVUS) has won an early weight-loss race in the marketplace. The company launched its Qsymia treatment, beating competitor Arena Pharmaceuticals' ($ARNA) Belviq by several months. But will it come out on top in the most important one--the contest for prescriptions and sales?
UPDATED: ScinoPharm will make API for blockbuster hopeful Qsymia
Taiwanese CMO ScinoPharm is looking to cash in on Vivus' diet drug, signing on to manufacture one of the pill's APIs.
